New British-Cuban Biotechnology Joint Venture Debuts in the UK
Published 20 November 2020 (1 hours 10 minutes ago)
The Cuban-British joint venture BioFarma Innovations was formally presented in the United Kingdom during an online seminar where Cuba's outstanding results in biotechnology were exhibited, according to the Caribbean nation's embassy in London on Friday.
At the event, which was sponsored by the Caribbean Council, the advantages derived from this economic and commercial association were analyzed in the presence of the executive director of that organization, Chris Bennet, the co-president of the Cuba Initiative, Lord David Triesman, and the development director of the Cuban company Hebert Biotec S.A., Merardo Pujol.
BioFarma Innovations, the result of an agreement between the Cuban company BioCubaFarma and the British company SG Innovations Ltd., was launched last August to expedite access of the British Commonwealth and Europe more generally to the broad portfolio of medicines patented by the Cuban biotechnology industry, as well as to its experience in the sector.
Under the title "Bringing Cuban biopharmaceuticals to patients worldwide: a new British-Cuban joint venture," the seminar also focused on issues such as the commercialization of pharmaceutical products in the world, the protection of intellectual property, as well as the opportunities that exist to expand this relationship and bring Cuban medicines to many more patients on the planet.
More:
https://www.telesurenglish.net/news/New-British-Cuban-Biotechnology-Joint-Venture-Debuts-in-the-UK-20201120-0013.html